Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 1
1988 3
1989 3
1990 2
1991 6
1992 7
1993 6
1994 2
1995 1
1996 3
1997 2
1998 6
1999 3
2002 1
2003 2
2004 10
2005 10
2006 8
2007 8
2008 5
2009 10
2010 12
2011 7
2012 11
2013 13
2014 17
2015 20
2016 20
2017 18
2018 20
2019 31
2020 42
2021 53
2022 61
2023 48
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Results by year

Filters applied: . Clear all
Page 1
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Male C, Lensing AWA, Palumbo JS, Kumar R, Nurmeev I, Hege K, Bonnet D, Connor P, Hooimeijer HL, Torres M, Chan AKC, Kenet G, Holzhauer S, Santamaría A, Amedro P, Chalmers E, Simioni P, Bhat RV, Yee DL, Lvova O, Beyer-Westendorf J, Biss TT, Martinelli I, Saracco P, Peters M, Kállay K, Gauger CA, Massicotte MP, Young G, Pap AF, Majumder M, Smith WT, Heubach JF, Berkowitz SD, Thelen K, Kubitza D, Crowther M, Prins MH, Monagle P; EINSTEIN-Jr Phase 3 Investigators. Male C, et al. Lancet Haematol. 2020 Jan;7(1):e18-e27. doi: 10.1016/S2352-3026(19)30219-4. Epub 2019 Nov 5. Lancet Haematol. 2020. PMID: 31699660 Free article. Clinical Trial.
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry.
Baggen J, Jacquemyn M, Persoons L, Vanstreels E, Pye VE, Wrobel AG, Calvaresi V, Martin SR, Roustan C, Cronin NB, Reading E, Thibaut HJ, Vercruysse T, Maes P, De Smet F, Yee A, Nivitchanyong T, Roell M, Franco-Hernandez N, Rhinn H, Mamchak AA, Ah Young-Chapon M, Brown E, Cherepanov P, Daelemans D. Baggen J, et al. Among authors: maes p. Cell. 2023 Aug 3;186(16):3427-3442.e22. doi: 10.1016/j.cell.2023.06.005. Epub 2023 Jul 7. Cell. 2023. PMID: 37421949 Free PMC article.
Towards engineering dreams.
Carr M, Haar Horowitz A, Amores J, Maes P. Carr M, et al. Among authors: maes p. Conscious Cogn. 2020 Oct;85:103006. doi: 10.1016/j.concog.2020.103006. Epub 2020 Aug 24. Conscious Cogn. 2020. PMID: 32854064 No abstract available.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Park YJ, Pinto D, Walls AC, Liu Z, De Marco A, Benigni F, Zatta F, Silacci-Fregni C, Bassi J, Sprouse KR, Addetia A, Bowen JE, Stewart C, Giurdanella M, Saliba C, Guarino B, Schmid MA, Franko NM, Logue JK, Dang HV, Hauser K, di Iulio J, Rivera W, Schnell G, Rajesh A, Zhou J, Farhat N, Kaiser H, Montiel-Ruiz M, Noack J, Lempp FA, Janer J, Abdelnabi R, Maes P, Ferrari P, Ceschi A, Giannini O, de Melo GD, Kergoat L, Bourhy H, Neyts J, Soriaga L, Purcell LA, Snell G, Whelan SPJ, Lanzavecchia A, Virgin HW, Piccoli L, Chu HY, Pizzuto MS, Corti D, Veesler D. Park YJ, et al. Among authors: maes p. Science. 2022 Nov 11;378(6620):619-627. doi: 10.1126/science.adc9127. Epub 2022 Oct 20. Science. 2022. PMID: 36264829 Free article.
Editorial: Neurotechnologies for Human Augmentation.
Valeriani D, Ayaz H, Kosmyna N, Poli R, Maes P. Valeriani D, et al. Among authors: maes p. Front Neurosci. 2021 Nov 11;15:789868. doi: 10.3389/fnins.2021.789868. eCollection 2021. Front Neurosci. 2021. PMID: 34858136 Free PMC article. No abstract available.
Enhancing human emotions with interoceptive technologies.
Schoeller F, Haar AJH, Jain A, Maes P. Schoeller F, et al. Among authors: maes p. Phys Life Rev. 2019 Dec;31:310-319. doi: 10.1016/j.plrev.2019.10.008. Epub 2019 Oct 25. Phys Life Rev. 2019. PMID: 31757602 Review.
Genome-wide CRISPR screening identifies TMEM106B as a proviral host factor for SARS-CoV-2.
Baggen J, Persoons L, Vanstreels E, Jansen S, Van Looveren D, Boeckx B, Geudens V, De Man J, Jochmans D, Wauters J, Wauters E, Vanaudenaerde BM, Lambrechts D, Neyts J, Dallmeier K, Thibaut HJ, Jacquemyn M, Maes P, Daelemans D. Baggen J, et al. Among authors: maes p. Nat Genet. 2021 Apr;53(4):435-444. doi: 10.1038/s41588-021-00805-2. Epub 2021 Mar 8. Nat Genet. 2021. PMID: 33686287
435 results